SIRIO(SZ:300791) Zheng Quan Zhi Xing·2025-07-18 16:19Core Viewpoint - The legal opinion letter issued by Guangdong Xinda Law Firm confirms that the adjustments to the 2023 and 2025 restricted stock incentive plans of Xianle Health Technology Co., Ltd. have obtained the necessary approvals and comply with relevant laws and regulations [1][14][20]. Group 1: 2023 Restricted Stock Incentive Plan - The 2023 incentive plan has undergone adjustments due to the company's capital reserve conversion and stock dividend distribution, affecting the repurchase price and quantity of restricted stocks [14][15]. - The initial grant price for the restricted stocks was adjusted from 9.78 yuan to 7.52 yuan per share, and the total number of restricted stocks granted was adjusted to 1,343,888 shares [15][16][20]. - The company has completed the registration of 1,094,275 shares for the initial grant and 249,613 shares for the reserved grant, with the listing date set for December 27, 2023 [7][9]. Group 2: 2025 Restricted Stock Incentive Plan - The 2025 incentive plan has also been adjusted, with the initial grant price set at 13.27 yuan per share, which was later adjusted to 10.21 yuan per share due to similar corporate actions [19][20]. - The total number of restricted stocks for the initial grant was adjusted to 1,821,300 shares, reflecting the company's capital reserve conversion and stock dividend distribution [20]. - The company has confirmed that the proposed recipients of the 2025 incentive plan meet all legal and regulatory requirements, with no objections raised during the public disclosure period [12][13].